Sanibel Captiva Trust Company Inc. Decreases Stake in Stryker Co. (NYSE:SYK)

Sanibel Captiva Trust Company Inc. lessened its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 3.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,107 shares of the medical technology company's stock after selling 1,509 shares during the quarter. Sanibel Captiva Trust Company Inc.'s holdings in Stryker were worth $18,280,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its position in Stryker by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock worth $11,773,213,000 after buying an additional 252,188 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Stryker by 0.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock valued at $4,000,056,000 after purchasing an additional 54,693 shares in the last quarter. FMR LLC grew its stake in shares of Stryker by 10.0% during the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after buying an additional 727,850 shares during the last quarter. Geode Capital Management LLC raised its position in Stryker by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock valued at $2,539,033,000 after purchasing an additional 168,436 shares during the last quarter. Finally, Norges Bank acquired a new stake in Stryker during the 4th quarter worth approximately $1,710,744,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Down 1.0%

Stryker stock traded down $4.02 during midday trading on Wednesday, reaching $381.03. The stock had a trading volume of 792,341 shares, compared to its average volume of 1,330,630. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a fifty day moving average price of $370.53 and a two-hundred day moving average price of $375.91. The company has a market capitalization of $145.43 billion, a P/E ratio of 49.10, a PEG ratio of 2.93 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. During the same quarter in the previous year, the business posted $2.50 EPS. Stryker's quarterly revenue was up 11.9% on a year-over-year basis. As a group, equities analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker's payout ratio is 45.41%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a research report on Tuesday, March 4th. Sanford C. Bernstein set a $450.00 price objective on Stryker in a report on Monday, May 5th. BTIG Research set a $403.00 target price on Stryker and gave the stock a "buy" rating in a report on Monday, April 14th. Roth Mkm upped their price target on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Finally, Needham & Company LLC reissued a "buy" rating and issued a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $427.30.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.